Evidence map›Paper›PMID 32488349›Full record

ArticlePsychopharmacology2020

Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews.

Erin M Rock, Megan T Sullivan, Stephen A Collins, Hannah Goodman, Cheryl L Limebeer, Raphael Mechoulam, Linda A Parker

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Cats and cannabinoids: past, present and future.Journal of feline medicine and surgery · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects.Journal of the National Cancer Institute. Monographs · 2021
    Article
  9. Review
  10. Article
  11. Review
  12. Cannabidiol and Other Cannabinoids in Demyelinating Diseases.International journal of molecular sciences · 2021
    Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Erin M RockDepartment of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada.
Megan T SullivanDepartment of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada.
Stephen A CollinsDepartment of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada.
Hannah GoodmanDepartment of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada.
Cheryl L LimebeerDepartment of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada.
Raphael MechoulamInstitute of Drug Research, Medical Facility, Hebrew University of Jerusalem, Jerusalem, Israel.
Linda A ParkerDepartment of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G2W1, Canada. parkerl@uoguelph.ca.ORCID http://orcid.org/0000-0002-3494-9754
University of Guelph · CAHebrew University of Jerusalem · IL

Funding

CIHR 388239Natural Sciences and Engineering Research Council of Canada 03629
6 · The paper itself

Abstract

rationaleWhen acutely administered intraperitoneally, the non-psychoactive cannabinoid cannabidiol (CBD), its acidic precursor cannabidiolic acid (CBDA) and a stable methyl ester of CBDA (HU-580) reduce lithium chloride (LiCl)-induced conditioned gaping in male rats (a selective preclinical model of acute nausea) via activation of the serotonin 1A (5-HT

objectivesTo utilise these compounds to manage nausea in the clinic, we must determine if their effectiveness is maintained when injected subcutaneously (s.c) and when repeatedly administered. First, we compared the effectiveness of each of these compounds to reduce conditioned gaping following repeated (7-day) and acute (1-day) pretreatments and whether these anti-nausea effects were mediated by the 5-HT

resultsBoth acute and repeated (7 day) s.c. administrations of CBD (5 mg/kg), CBDA (1 μg/kg) and HU-580 (1 μg/kg) similarly reduced LiCl-induced conditioned gaping, and these effects were blocked by 5HT

conclusionWhen administered repeatedly (7 days), CBD, CBDA and HU-580 did not lose efficacy in reducing nausea and continued to act via agonism of the 5-HT

Indexed as

AnimalsAntiemeticsCannabidiolCannabinoidsDrug Administration ScheduleFemaleLithium ChlorideMaleNauseaRatsRats, Sprague-DawleyShrewsTreatment OutcomeVomitingAntiemeticsCannabidiolcannabidiolic acidCannabinoidsHU-580Lithium Chloride5-HT1ACannabidiolCannabidiolic acidConditioned gapingHU-580Repeated

Identifiers

PMID32488349
OpenAlexW3030108781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.